Dyne Therapeutics, Inc. (DYN)
Nasdaq: DYN · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Mar 2, 2026 | Feb 27, 2025 | Mar 5, 2024 | Mar 2, 2023 | Mar 10, 2022 | Mar 4, 2021 | · |
| Research and development | 398,333 | 281,406 | 210,762 | 142,760 | 121,308 | 45,200 | 11,040 |
| General and administrative | 69,851 | 62,480 | 31,400 | 28,202 | 28,717 | 13,447 | 2,786 |
| Total operating expenses | 468,184 | 343,886 | 242,162 | 170,962 | 150,025 | 58,647 | 13,826 |
| Operating income | -468,184 | -343,886 | -242,162 | -170,962 | -150,025 | -58,647 | -13,826 |
| Interest and investment income | 29,859 | 26,922 | 7,641 | 2,917 | 742 | 56 | 290 |
| Other income (expense), net | 21,970 | 26,468 | 6,225 | 2,863 | 734 | -790 | -1,033 |
| Income tax expense | 0 | 0 | 0 | · | · | · | · |
| Net income including non-controlling interests | -446,214 | -317,418 | -235,937 | -168,099 | -149,291 | -59,437 | -14,859 |
| Net income | -446,214 | -317,418 | -235,937 | -168,099 | -149,291 | -59,437 | -14,859 |
| Earnings per share, basic | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | · | · |
| Earnings per share, diluted | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.93 | -4.13 | -6.08 |
| Weighted average shares, basic and diluted | · | · | · | · | 50,895,044 | 14,395,955 | 2,442,872 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted